Notice of Zealand’s Interim Report for H1 2015 and related conference call
Copenhagen, 2015-08-27 08:00 CEST (GLOBE NEWSWIRE) -- 27 August 2015 - Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) will release its interim report for the 1st half of 2015 tomorrow morning, Friday 28 August 2015 in accordance with the company’s financial calendar.
Conference call – Friday, 28 August at 14.00 CET/ 08.00 EDT
Zealand’s management will present the report and financial results for H1 2015 on a conference call tomorrow. Participating in the call will be Britt Meelby Jensen, President and Chief Executive Officer, Mats Blom, Chief Financial Officer, and Hanne Leth Hillman, Senior Vice President for Investor Relations and Communications. The presentation will be conducted in English and followed by a Q&A session.
The dial-in numbers are:
DK standard access +45 32 71 16 58
UK and international +44 (0) 20 3427 1906
US (free dial-in) +1 877 280 1254
A live audiocast of the call with an accompanying slide presentation will be available via the following link: http://edge.media-server.com/m/p/xoisirgi, accessible also from the front page of the company’s website (www.zealandpharma.com). Participants are advised to register for the audiocast approximately 10 minutes before the start.
A replay of the event will be made available from the Investor section of Zealand’s website following the call.
●●●●●
For further information, please contact:
Hanne Leth Hillman, Senior Vice President for Investor Relations and Communications
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com
About Zealand Pharma
Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) is a biotechnology company with leading expertise in the identification, design and development of novel peptide medicines. Zealand has a proprietary pipeline of novel drug candidates, which is being advanced in development in-house, and a portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim – primarily in the fields of cardio-metabolic diseases and acute care indications. The proprietary pipeline include danegaptide for Ischemic Reperfusion Injury in Phase II development and the stable glucagon analogue, ZP4207 in two clinical development programs; as a ready-to-use rescue pen for severe hypoglycemia in preparation for Phase II and as a multiple-dose version for mild to moderate hypoglycemia in Phase I, as well as several preclinical peptide therapeutics.
Zealand has invented lixisenatide, a once-daily prandial GLP-1 agonist, which is marketed globally (ex-US) by Sanofi for the treatment of Type 2 diabetes. Sanofi submitted lixisenatide for regulatory approval in the US in late July 2015, and has a combination of lixisenatide with insulin glargine (Lantus®) in Phase III development with regulatory submissions expected in Q4 2015 in the US and in Q1 2016 in Europe.
The company is based in Copenhagen (Glostrup), Denmark. For further information about our company and activities, please visit: www.zealandpharma.com
Vedhæftede filer:
05_15-0827 - Notice of H1 Interim Report and Related Conference Call_ENG_FINAL.pdf